All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

/images/Cortellis_Flagship_Logo_TM_RGB_Color.png
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Artificial intelligence
    • Coronavirus
    • Diagnosing and tracking COVID-19
    • Drugs to Watch 2020
    • The next pandemic
    • Premium reports
      • BioWorld Financings Reports
      • Disease Forecast Reports

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, February 26, 2021
Home » Topics » Infection, BioWorld

Infection, BioWorld
%{topic} RSS Feed RSS

Petri dish and capsules

Awaiting FDA decision on ibrexafungerp, Scynexis deals greater China rights to Hansoh

Feb. 19, 2021
By David Ho
No Comments
HONG KONG – Hansoh Pharmaceutical Group Co. Ltd. picked up the greater China rights to Scynexis Inc.’s lead candidate, ibrexafungerp. Under the terms, Hansoh will take charge of the development, regulatory approval and commercialization of the antifungal in the region in exchange for a $10 million up- front payment and as much as $112 million in development and commercial milestones, plus low double-digit royalties on net product sales.
Read More

Ferring expands Mybiotics ties with deal for development of microbiota-based BV therapy

Feb. 18, 2021
By David Ho
No Comments
HONG KONG – Ferring Pharmaceuticals’ microbiome-focused subsidiary Rebiotix Inc. and Mybiotics Pharma Ltd. have agreed to a multiyear strategic collaboration to develop live microbiota-based biotherapeutics to address bacterial vaginosis (BV). The companies did not disclose the financials of the deal.
Read More
CRISPR illustration

Excision adds a $60M funding to develop CRISPR-based therapies

Feb. 17, 2021
By Lee Landenberger
No Comments
Excision Biotherapeutics Inc.’s CEO is specific when he talks about his company’s therapies and what they may achieve: a functional cure. “When you treat someone and they become cancer free, you can’t use the world ‘cured’ because the cancer may come back decades later,” Daniel Dornbusch told BioWorld. “But you can talk about a  functional cure, meaning the cancer didn’t come back for a very long time. It’s functionally cured for maybe 10, 20 or 30 years."
Read More
Cytomegalovirus in a human cell

Spybiotech closes $32.5M round to bring CMV vaccine into the clinic

Feb. 10, 2021
By Cormac Sheridan
No Comments
DUBLIN – Spybiotech Ltd. raised $32.5 million to move into clinical trials its first in-house vaccine program based on its Spycatcher/Spytag protein conjugation technology. The company is gearing up to start a phase I trial of a vaccine directed against cytomegalovirus (CMV) early next year.
Read More

Botanix’s cannabidiol eradicates Staphylococcus aureus bacteria in phase IIa nasal colonization study

Feb. 4, 2021
By Tamra Sami
No Comments
PERTH, Australia – Synthetic cannabinoid company Botanix Pharmaceuticals Ltd. announced top-line data from a phase IIa study showing that two different formulations of BTX-1801, a synthetic cannabidiol, eradicated Staphylococcus aureus (staph) in the nose, meeting study endpoints for safety and efficacy. 
Read More

PD-1 checkpoint blockade can backfire in TB, study shows

Jan. 20, 2021
By Anette Breindl
No Comments
Researchers at the National Institute of Allergy and Infectious Diseases have shown that optimal control of tuberculosis (TB) infection necessitated immune regulation as well as immune activation – and that PD-1 checkpoint blockers exacerbated TB infections in macaque monkeys by disrupting the balance between the two.
Read More
Mosaico team in Mexico City

First-ever phase III trials of HIV vaccine in Latin America

Jan. 11, 2021
By Sergio Held
No Comments
CAJICA, Colombia – A phase III trial for an HIV vaccine developed Janssen Vaccines & Prevention BV is finally moving forward in Latin America and elsewhere in the world after a delay of more than a year caused by slow regulatory progress and worsened by a string of COVID-19 lockdowns.
Read More
Pregnancy

Minervax closes $58M series B round for group B strep vaccine

Dec. 15, 2020
By Cormac Sheridan
No Comments
DUBLIN – Minervax Aps raised €47.4 million (US$57.6 million) in a series B funding round to take a recombinant-protein-based vaccine for group B streptococcus (GBS) through a phase II program as well as parallel surveillance studies to enable it to define correlates of protection against GBS in newly born infants.
Read More

Bankin’ sense and Myr: Gilead’s $1.4B deal in HDV gifts Eiger shares

Dec. 10, 2020
By Randy Osborne
No Comments
Gilead Sciences Inc.’s move to grab Myr GmbH for about €1.15 billion (US$1.39 billion) in cash up front, with €300 million if the latter’s Hepcludex (bulevirtide) wins FDA clearance, put chronic hepatitis delta virus (HDV) in the headlines and benefited the stock of another player in the space: Eiger Biopharmaceuticals Inc. (NASDAQ:EIGR), which closed at $10.27, up $1.51, or 17%.
Read More
Cytomegalovirus in a human cell

Takeda reports success for maribavir in tough post-transplant CMV cases

Dec. 4, 2020
By Michael Fitzhugh
No Comments
New phase III data on Takeda Pharmaceutical Co. Ltd.'s TAK-620 (maribavir) for the treatment of transplant recipients with tough-to-treat cytomegalovirus (CMV) infections met the trial's primary endpoint, setting the company up to file an NDA for the oral antiviral in the first half of next year.
Read More
Previous 1 2 3 4 5 6 7 8 9 … 13 14 Next

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld

    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus outbreak. Note that we have added three critical tables which are...

  • Seniors with wooden puzzle

    Cassava’s simufilam improves AD patients’ cognition, behavior

    BioWorld
    When Cassava Sciences Inc.’s president and CEO, Remi Barbier, opened up the interim analysis of the company’s open-label study for Alzheimer’s disease candidate...
  • Vaxart COVID-19 vaccine tablets

    Vaxart shares shaken despite apparently positive early data for oral COVID-19 vaccine

    BioWorld
    Vaxart Inc. investors who stuck by company shares Feb. 3 had to swallow a bitter pill – watching shares of the oral vaccine developer (NASDAQ:VXRT) fall 57.8% to...
  • IPO money

    Lucira Health launches $153M IPO

    BioWorld MedTech
    Infectious diseases diagnostics company Lucira Health Inc. launched an IPO of 9 million shares of common stock at $17 per share, for expected gross proceeds of...
  • Today's news in brief

    BioWorld
    BioWorld briefs for Feb. 25.
cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • About
    • Archives
    • Today's news
    • Search BioWorld Science
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
A Clarivate Analytic solution. Link to Clarivate website.
Follow Us

Copyright ©2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing